Several autoimmune diseases can attack the eyes, but the most common are Graves’ disease (thyroid eye disease), Sjögren’s syndrome, and the group of conditions that cause uveitis, including rheumatoid arthritis, lupus, sarcoidosis, and Behçet’s disease. Some of these target the eye directly, while others cause eye damage as part of a body-wide inflammatory process. The type of eye involvement, and how serious it becomes, depends on which condition is driving the attack.
Thyroid Eye Disease (Graves’ Disease)
Graves’ disease is the autoimmune condition most visibly associated with the eyes. The immune system produces antibodies that stimulate receptors on cells behind the eyeball, triggering those cells to produce excess tissue and fluid. This causes the fat and muscle behind the eye to swell, physically pushing the eyeball forward in what’s sometimes called “bulging eyes.” The swelling can also compress the optic nerve and restrict eye movement, leading to double vision.
The biology is specific: antibodies meant for the thyroid gland cross-react with receptors on cells in the eye socket called orbital fibroblasts. When activated, these cells overproduce a gel-like substance called hyaluronan and generate new fat tissue, both of which take up space in the rigid bony orbit. The result is inflammation, pressure, and visible changes to the eyes that can develop over weeks or months, sometimes before thyroid problems are even diagnosed.
A newer treatment blocks one of the key receptors involved in this process. In clinical use, roughly one in four patients treated with this therapy need a second course within a year, with older age being the main predictor of retreatment. Older approaches include steroids, radiation to the eye socket, and surgical decompression to relieve pressure.
Sjögren’s Syndrome and Severe Dry Eye
Sjögren’s syndrome attacks the glands that produce tears and saliva. The immune system sends white blood cells into these glands, gradually destroying their ability to function. The result is chronic, severe dry eye that goes well beyond the occasional grittiness most people experience. Without adequate tear production, the surface of the eye becomes inflamed and damaged, a condition called keratoconjunctivitis sicca.
Diagnosing Sjögren’s-related dry eye involves measuring tear production with a small strip of paper placed under the lower eyelid. A result below 5 millimeters of wetting is considered abnormally low. Doctors also look for surface damage on the cornea using special dyes, test salivary gland flow, check for specific antibodies in the blood (anti-Ro and anti-La), and sometimes biopsy a small salivary gland inside the lip to look for clusters of immune cells. Meeting three of four established criteria is enough for a presumptive diagnosis.
Sjögren’s can exist on its own (primary) or alongside another autoimmune disease like rheumatoid arthritis or lupus (secondary). Treatment focuses on replacing moisture with artificial tears, prescription eye drops that reduce inflammation on the eye surface, and sometimes small plugs inserted into the tear ducts to keep whatever tears you produce from draining away too quickly.
Uveitis: When Inflammation Strikes Inside the Eye
Uveitis is inflammation of the middle layer of the eye wall, and autoimmune disease is one of its leading causes. It can affect the front of the eye (causing redness, pain, and light sensitivity), the back of the eye (threatening the retina and optic nerve), or both. Unlike a standard eye infection, autoimmune uveitis tends to recur and can smolder for months without obvious symptoms, quietly damaging structures inside the eye.
Several autoimmune conditions significantly raise the risk. Children with juvenile idiopathic arthritis face roughly five times the normal risk of developing uveitis, often with few outward signs, which is why routine eye screening is critical for these kids. Sarcoidosis carries about 3.7 times the usual risk. Lupus, inflammatory bowel disease, and ankylosing spondylitis are also well-established triggers.
Among people with posterior uveitis (affecting the back of the eye), nearly half develop some degree of visual impairment. Macular edema, where fluid accumulates in the central part of the retina, is the most common cause of vision loss, affecting about 28% of these patients. Other complications include glaucoma from chronic inflammation or long-term steroid use, and in some cases retinal detachment.
Behçet’s Disease
Behçet’s disease is a less common autoimmune condition that causes inflammation in blood vessels throughout the body, and the eyes are one of its primary targets. The hallmark finding is uveitis with a visible layer of white blood cells pooling in the front chamber of the eye, a sign called hypopyon. Behçet’s can also damage the retinal blood vessels, causing them to leak, become blocked, or develop abnormal new growth. Over time, this leads to areas of the retina that lose their blood supply entirely.
The disease is most prevalent along the ancient Silk Road region, from the Mediterranean through East Asia, and tends to be more severe in young men. Neurological involvement can cause optic nerve inflammation, visual field defects, and cranial nerve problems that affect eye movement. Because Behçet’s-related eye disease tends to be aggressive and recurring, treatment typically combines immune-suppressing medications rather than relying on steroids alone.
Optic Neuritis and Multiple Sclerosis
Optic neuritis is inflammation of the optic nerve that causes sudden vision loss, usually in one eye, often accompanied by pain during eye movement. It’s one of the most common first signs of multiple sclerosis. Within one year of a first episode, the overall risk of being diagnosed with MS is about 42%. Even among people whose initial brain scans look completely normal, roughly 20% go on to develop MS.
The mechanism is demyelination: the immune system strips away the protective insulation around nerve fibers, disrupting the signals traveling from the eye to the brain. Most people recover significant vision within weeks to months after an episode, but repeated attacks can cause permanent damage. Optic neuritis can also occur with lupus, sarcoidosis, and other inflammatory conditions, so a first episode typically prompts testing for multiple possible autoimmune causes.
Symptoms That Suggest Autoimmune Eye Disease
Ordinary eye infections and allergies share some symptoms with autoimmune eye conditions, which can delay diagnosis. A few patterns are more suggestive of an autoimmune cause:
- Deep, boring eye pain that doesn’t respond to over-the-counter drops, especially if it worsens with eye movement. This pattern is common in scleritis (inflammation of the white outer wall of the eye), which is strongly linked to rheumatoid arthritis and other connective tissue diseases.
- Light sensitivity out of proportion to redness. Mild redness with severe photophobia suggests inflammation inside the eye rather than on its surface.
- Recurrent episodes. A single bout of pink eye is almost never autoimmune. Repeated flares of redness, pain, or blurred vision in the same or alternating eyes raise suspicion.
- Vision changes with no external signs. Posterior uveitis and optic neuritis can cause blurred or dimmed vision without any visible redness, making them easy to dismiss.
- Eye symptoms alongside joint pain, mouth sores, rashes, or fatigue. Autoimmune eye disease rarely exists in isolation. Systemic clues often point to the underlying diagnosis.
How Autoimmune Eye Conditions Are Treated
Treatment follows a stepwise approach. Corticosteroid eye drops or injections are usually the first line for acute flares, aimed at quickly suppressing inflammation. For chronic or recurring disease, doctors move to longer-term immune-suppressing medications to reduce the need for steroids, which cause their own problems (cataracts and glaucoma) when used for extended periods.
For non-infectious uveitis specifically, adalimumab is currently the only biologic therapy with formal approval, granted for adults in 2016 and children in 2017. It works by blocking a key inflammatory signaling molecule. One important finding from clinical research: when patients achieve remission and attempt to taper off the medication, faster tapering leads to higher recurrence rates. For every additional 10 weeks a patient stays in remission before starting to taper, the chance of a flare drops by about 3.6%.
Other biologic therapies targeting the same inflammatory pathway are used off-label when the approved option isn’t effective or isn’t tolerated. For conditions like Behçet’s disease and juvenile arthritis-related uveitis, combining a biologic with a traditional immune suppressant like methotrexate is often recommended. The overarching goal across all these conditions is the same: control inflammation aggressively enough to prevent the cumulative, irreversible damage that leads to permanent vision loss.